AB-MDMSBA is a novel synthetic compound that has been sold as a designer drug. It has been detected by drug checking services in Australia and New Zealand being misrepresented as a benzodiazepine.
It is structurally similar to other arylsulfonamide-based synthetic cannabinoids such as QMPSB. This class of synthetic cannabinoid has previously been targeted toward greater selectivity of the cannabinoid receptor CB<sub>2</sub> over CB<sub>1</sub>. The activity of AB-MDMSBA against either cannabinoid receptor is unknown.